Warnings, Columns-Drugs & Supplements, October 2005

September 26, 2005

Bristol-Myers Squibb and ImClone Systems Update Erbitux Warnings NEW YORK - Bristol-Myers Squibb Co. and ImClone Systems Inc. recently announced updated warnings for their colorectal cancer drug Erbitux (cetuximab) to reflect increased concerns over patients' adverse reactions. The precautions and adverse reactions sections now include information regarding an increased incidence of hypomagnesemia seen in clinical trials and recommendations for electrolyte monitoring, the companies said in a Sept. 13 letter to the Food and Drug Administration. The companies said the warnings and dosage and administration sections also include a recommendation that healthcare providers observe patients for … Subscribe Now Purchase Article for $40.00 Registered User Log In Email Address Password Login Forgot your username or password? UPCOMING CONFERENCES HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates May 29, 2024 - Salt Lake City, UT The Grand America Hotel MORE DETAILS HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone June 27, 2024 - Buffalo, NY The Richardson Hotel Buffalo MORE DETAILS Sign Up For Email Alerts × Email address Publications Asbestos Benzene & Emerging Toxic Torts Litigation Camp Lejeune & Water Contamination Drugs & Medical Devices MDL Mass Tort & Class Action Monitor Reinsurance & Arbitration Talcum Powder Litigation Report Close Submit